CytoMed Therapeutics Announces Promising Preclinical Results for Allogeneic γδ T Cell Therapy in Acute Myeloid Leukemia, Plans Clinical Trials in Southeast Asia
Reuters
Oct 02, 2025
CytoMed <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Promising Preclinical Results for Allogeneic γδ T Cell Therapy in Acute Myeloid Leukemia, Plans Clinical Trials in Southeast Asia
CytoMed Therapeutics Ltd. has announced the publication of preclinical research results from a collaborative study with The University of Texas MD Anderson Cancer Center, evaluating the potential of allogeneic γδ T cell therapy (CTM-GDT) for the treatment of acute myeloid leukemia (AML). The findings, now available in the research article "Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising 'Off-the-Shelf' Immunotherapy Approach," suggest that donor-derived γδ T cells may offer a promising immunotherapy option for AML. The company stated that these preclinical results provide a basis for advancing this therapy into future clinical trials in Southeast Asia. CytoMed's lead γδ T cell-based product, CAR-γδ T cells (CTM-N2D), is currently in Phase 1 clinical trials in Singapore.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9539088-en) on October 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.